Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2)

Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) is a member of the Class III subfamily of receptor tyrosine kinases plays an essential role in angiogenesis. Expression is almost exclusively restricted to endothelial cells. It acts as a cell-surface receptor for VEGF-A, VEGF-C, and VEGF-D and it plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. VEGFR-2 promotes proliferation, survival, migration, and differentiation of endothelial cells. It promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGF-A, VEGF-C and/or VEGF-D. Isoform 2 plays an important role as negative regulator of VEGF-A- and VEGF-C-mediated lymphangiogenesis by limiting the amount of free VEGF-A and/or VEGF-C and preventing their binding to FLT4. VEGFR-2 modulates FLT1 and FLT4 signaling by forming heterodimers. The binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate in addition to the activation of protein kinase C. It also mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway.

Swiss-Prot Accession Number: P35968

Myriad RBM Publications Publications
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Variation in Serum Biomarkers with Sex and Female Hormonal Status: Implications for Clinical Tests (2016) Ramsey JM, Cooper JD, Penninx BWJH, Bahn S Scientific Reports
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (2016) Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J. Cancer